NasdaqCM:VTGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. More Details


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has VistaGen Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VTGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.2%

VTGN

0.4%

US Biotechs

1.3%

US Market


1 Year Return

-40.4%

VTGN

37.9%

US Biotechs

15.8%

US Market

Return vs Industry: VTGN underperformed the US Biotechs industry which returned 35.6% over the past year.

Return vs Market: VTGN underperformed the US Market which returned 13.8% over the past year.


Shareholder returns

VTGNIndustryMarket
7 Day3.2%0.4%1.3%
30 Day-8.4%0.4%-4.1%
90 Day18.9%-3.6%8.4%
1 Year-40.4%-40.4%40.4%37.9%18.4%15.8%
3 Year-60.5%-60.5%14.4%8.9%38.2%29.0%
5 Year-93.3%-93.3%22.8%14.1%84.9%64.0%

Price Volatility Vs. Market

How volatile is VistaGen Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is VistaGen Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether VistaGen Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as VistaGen Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is VistaGen Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

49.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VTGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VTGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VTGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if VTGN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if VTGN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VTGN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has VistaGen Therapeutics performed over the past 5 years?

14.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VTGN is currently unprofitable.

Growing Profit Margin: VTGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VTGN is unprofitable, but has reduced losses over the past 5 years at a rate of 14.1% per year.

Accelerating Growth: Unable to compare VTGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VTGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: VTGN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is VistaGen Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: VTGN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VTGN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VTGN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VTGN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VTGN has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: Insufficient data to determine if VTGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is VistaGen Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VTGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VTGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VTGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VTGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VTGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.0yrs

Average management tenure


CEO

Shawn Singh (57 yo)

9.33yrs

Tenure

US$933,667

Compensation

Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd. ...


CEO Compensation Analysis

Compensation vs Market: Shawn's total compensation ($USD933.67K) is above average for companies of similar size in the US market ($USD604.44K).

Compensation vs Earnings: Shawn's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Shawn Singh
CEO & Director9.33yrsUS$933.67k0.076%
$ 35.8k
H. Snodgrass
Founder22.67yrsUS$671.26k0.11%
$ 52.3k
Jerrold Dotson
CFO, VP & Secretary9yrsUS$597.07k0.0068%
$ 3.2k
Mark McPartland
Vice President of Corporate Development3.92yrsUS$479.99k0%
$ 0
Mark Smith
Chief Medical Officer4.25yrsUS$596.84k0.0068%
$ 3.2k

9.0yrs

Average Tenure

65yo

Average Age

Experienced Management: VTGN's management team is seasoned and experienced (9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Shawn Singh
CEO & Director9.33yrsUS$933.67k0.076%
$ 35.8k
H. Snodgrass
Founder22.67yrsUS$671.26k0.11%
$ 52.3k
Jon Saxe
Independent Chairman20.67yrsUS$153.85k0.072%
$ 33.7k
Jerry Gin
Independent Director4.5yrsUS$151.35k0.14%
$ 63.2k
Brian Underdown
Independent Director10.83yrsUS$153.85k0%
$ 0
George Clay
Member of Scientific Advisory Boardno datano datano data
Gordon Keller
Chairman of Scientific Advisory Boardno datano datano data
Maurizio Fava
Chairman of Clinical & Regulatory Advisory Board4.5yrsno datano data
James Sanders
Member of Scientific Advisory Boardno datano datano data
Ron Wester
Member of Scientific Advisory Boardno datano datano data
Gerard Sanacora
Member of Clinical & Regulatory Advisory Board5.5yrsno datano data
Sanjay Matthew
Member of Clinical & Regulatory Advisory Board4.5yrsno datano data

8.2yrs

Average Tenure

77yo

Average Age

Experienced Board: VTGN's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VTGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.6%.


Top Shareholders

Company Information

VistaGen Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: VistaGen Therapeutics, Inc.
  • Ticker: VTGN
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$46.782m
  • Shares outstanding: 74.00m
  • Website: https://www.vistagen.com

Number of Employees


Location

  • VistaGen Therapeutics, Inc.
  • 343 Allerton Avenue
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VTGNNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDMay 2011

Biography

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on dep ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/29 00:35
End of Day Share Price2020/09/28 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.